Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme in the mevalonate pathway, responsible for cholesterol biosynthesis. It is a key therapeutic target for statin drugs, which lower cholesterol levels and reduce cardiovascular risk.
Competitive inhibition of HMGCR, blocking the conversion of HMG-CoA to mevalonic acid, thereby reducing cholesterol synthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR).